Skip to main content
SpringerLink
Log in

Hormontherapie nach gynäkologischen Tumoren

  • Conference paper
Gießener Gynäkologische Fortbildung 2003

  • 58 Accesses

Zusammenfassung

Frauen, mit einer malignen Erkrankung des Genitale oder der Brust, leiden häufig nicht nur unter der Erkrankung selber, sondern auch an Nebenwirkungen bedingt durch einen Östrogenentzug, sei dies nun Medikamenten bedingt wie beim Mammakarzinom oder auf die Ovarektomie im Rahmen der Primärtherapie zurückzuführen. Aufgrund des Östrogenmangels kommt es zu klimakterischen Beschwerden wie Hitzewallungen (s. Übersicht 1), Libidoverlust, Scheidentrockenheit, Stimmungsschwankungen, Schlafstörungen aber auch zu längerfristigen Problemen wie Osteoporose, kardiovaskulären Risiken oder Hautveränderungen (Übersichten 2 und 3). Deshalb ist es wichtig, auch diesen Patientinnen bei entsprechenden Beschwerden eine Therapie nach gründlichem Abwägen des Nutzen und Risikos anbieten zu können.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 44.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 59.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Hempling RE, Wong C, Pier MS, Natarajan N, Met-lin CJ (1997) Hormone replacement therapy and risk of factor for epithelial ovarian cancer: results of a case control study. Obstet Gynecol 89: 1012–1016

    Article  PubMed  CAS  Google Scholar 

  2. Purdie DM, Bain CJ, Siskind V, Russell P, Hacker NF, Ward BG, Quinn MA, Green AC (1999) Hormone replacement therapy and risk of epithelial ovarian cancer. Br J Cancer 81: 559–563

    Article  PubMed  CAS  Google Scholar 

  3. Guidozzi F, Daponte A (1999) Estrogen replacement therapy for ovarian carcinoma survivors: a randomized controlled trial. Cancer 86: 1013–1018

    Google Scholar 

  4. Barret-Connor E (1992) Hormone-replacement and cancer. Br Med Bull 48: 345–355

    Google Scholar 

  5. Thigpen JT, Brady MF, Alvarez RD, Adelson MD, Homesley HD, Manetta A, Soper JT, Given FT (1999) Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gyneco-logic Oncology Group. J Clin Oncol 17: 1736–1744

    PubMed  CAS  Google Scholar 

  6. Von Minckwitz G, Loibl S, Brunnert K, Kreienberg R, Melchert F, Mosch R, Neises M, Schermann J, Seufert R, Stiglmayer R, Stosiek U, Kaufmann M (2002) Adjuvant endocrine treatment with medroxyprogesterone acetate or tamoxifen in stage I and II endometrial cancer-a multicentre, open, controlled, prospectively randomised trial. Eur J Cancer 38: 2265–2271

    Article  Google Scholar 

  7. Lee RB, Burke TW, Park RC (1990) Estrogen repla-cement therapy following treatment for stage I endometrial carcinoma. Gynecol Oncol 36: 189–191

    Article  PubMed  CAS  Google Scholar 

  8. Creasman WT (1991) Estrogen replacement the-rapy: is previously treated cancer contraindication? Obstet Gynecol 77: 308–312

    Article  PubMed  CAS  Google Scholar 

  9. Suriano KA, McHale M, McLaren CE, Li KT, Re A, DiSaia PJ (2001) Estrogen replacement therapy in endometrial cancer patients: a matched control study. Obstet Gynecol 97: 555–56o

    Article  PubMed  CAS  Google Scholar 

  10. Parazzini F, La Vecchia C, Negri E, Franceschi S, Moroni S, Chatenoud L, Bolis G (1997) Case-con-trol study of oestrogen replacement therapy and risk of cervical cancer. BMJ 315: 85–88

    Article  PubMed  CAS  Google Scholar 

  11. Ploch E (1987) Hormone replacement therapy in patients after cervical cancer treatment. Gynecol Oncol 26: 169–177

    Article  PubMed  CAS  Google Scholar 

  12. Burger CW, van Leeuwen FE, Scheele F, Kenemans P (1999) Hormone replacement therapy in women treated for gynecological cancer. Maturitas 32: 69–76

    Article  PubMed  CAS  Google Scholar 

  13. Meurer LN, Lena SJ (2oo2) Cancer recurrence and mortality in women using hormone replacement therapy: meta-analysis. Fam Pract 51: io56-io62

    Google Scholar 

  14. Porch JV, Lee IM, Cook NR, Rexrode KM, Burin JE (2002) Estrogen-progestin replacement therapy and breast cancer risk: the Women’s Health Study ( United States ). Cancer Caus Contr 3: 847–854

    Article  Google Scholar 

  15. Weiss LK, Burkman RT, Cushing-Haugen KL et al. (2002) Hormone replacement therapy regimens and breast cancer risk (1). Obstet Gynecol 100: 1148–1158

    Article  PubMed  CAS  Google Scholar 

  16. Peethambaram PP, Ingle JN, Suman VJ, Hartmann LC, Loprinzi CL (1999) Randomized trial of diet-halstilbestrol vs tamoxifen in postmenopausal women with metastatic breast cancer. An updated analysis. Breast Cancer Res Treat 54: 117–122

    Article  PubMed  CAS  Google Scholar 

  17. Stoll BA (1989) Hormone replacement therapy in women treated for breast cancer. Eur J Cancer Clin Oncol 25: 1909–1913

    Article  PubMed  CAS  Google Scholar 

  18. Wile AG, Opfell RW, Margileth DA (1993) Hor-mone replacement therapy in previously treated breast cancer patients. Am J Surg 165: 372–375

    Article  PubMed  CAS  Google Scholar 

  19. Eden JA, Bush T, Nand S, Wren BG (1995) A case-control sutdy of combined continous estrogen-progestogen replacement among women with a personal history of breast cancer. Menopause 2: 67–72

    Article  Google Scholar 

  20. Horn-Ross PL (1993) Multiple primary cancers involving the breast. Epidemiol Rev 15: 67–72

    Google Scholar 

  21. Carpenter JS, Johnson DH, Wagner LJ, Andrykowski MA (2002) Got flashes and related outcomes in breast cancer survivors and matched comparison women. Oncol Nurs Forum 29 (3): E 16–25

    Article  Google Scholar 

  22. Loprinzi CL, Kugler JW, Sloan JA, Mailliard JA, LaVasseur BI, Barton DL, Novotny PJ, Dakhil SR, Rodger K, Rummans TA, Christensen BJ (2000) Venlafaxine in management of hot flashes in sur-vivors of breast cancer: a randomised controlled trial. Lancet 356: 2059–2063

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. S. Loibl
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Kaufmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Loibl, S., Kaufmann, M. (2003). Hormontherapie nach gynäkologischen Tumoren. In: Gießener Gynäkologische Fortbildung 2003. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-07492-3_24

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-07492-3_24

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-04757-5

  • Online ISBN: 978-3-662-07492-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation